| خلاصه مقاله | commonly severe in gastrointestinal tumors compared with anemia as a paraneoplastic phenomenon in other malignancies. The presence of anemia is related to aggressive tumor behavior and poor prognosis through exacerbating tumor hypoxia. Pretreatment anemia has shown significant prognostic value in solid cancers, including tumors of the rectum, stomach, esophagus, uterine cervix, and bladder. The aim of this study was to investigate the effect of hemoglobin levels on the survival rate of rectal cancer.
Method: In this retrospective cohort study, 378 cases of RC were recorded from medical centers. Patients were divided into three groups based on hemoglobin levels, Anemia was Hb< 13 g/dL in men, and less than 12 g/dL in women. Severe anemia was Hb below 10 g/ dL. Data were analyzed using the Kaplan-Meier method and log-rank test for the univariate analysis of survival in various groups and p value < 0.05 was set as statistically significant.
Result:
Of the 378 patients analyzed, 223 (59 %) were males. The mean age was 57.7 ± 14.4, ranging from 15 to 86 years. The most common presenting was hematochezia (75.9%).
The median Hb level was 12.50 g/dl, minimum 5.3 and maximum 19.9.
The Pretreatment Hb value was inversely related to the pretreatment T stage of the tumor (P = 0.01).
The median survival for mild anemia and severe anemia with local stage and highly stage were 50.33 Vs 27.7 and 26.4Vs 26.67 months respectively (p<0.05).
The five-year survival rate among RC patients without anemia was 55%, compared to 39% for mild anemia and 32% for severe anemia (p<0.05) [Figure 1].
In conclusions- the pretreatment Hb level might be used as a biomarker of rectal tumor extension (T) and prognosis determination. |